1. SCCS OPINION on Genistein and Daidzein - SCCS/1641/22 Final version
- Author
-
Bernauer, U., Bodin, L., Chaudhry, Q., Coenraad, P. J., Dusinska, M., Ezendam, J., Eric GAFFET, Galli, C. L., Granum, B., Panteri, E., Rogiers, V., Ch. Rousselle, Stepnik, M., Vanhaecke, T., Wijnhoven, S., Cabaton, N., Koutsodimou, A., Uter, W., Goetz, N., Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Scientific Committee for Consumer Safety (SCCS) (SCCS), Institut Jean Lamour (IJL), Institut de Chimie du CNRS (INC)-Université de Lorraine (UL)-Centre National de la Recherche Scientifique (CNRS), Direction des affaires européennes et internationales (DAEI), Agence nationale de sécurité sanitaire de l'alimentation, de l'environnement et du travail (ANSES), and Scientific Committee for Consumer Safety (SCCS, EC)
- Subjects
SCCS ,EC No 207-174-9) ,Regulation 1223/2009 ,daidzein (CAS No 486-66-8 ,[PHYS.COND.CM-MS]Physics [physics]/Condensed Matter [cond-mat]/Materials Science [cond-mat.mtrl-sci] ,EC No 207-635-4) ,scientific opinion ,genistein (CAS No 446-72-0 - Abstract
International audience; SCCS OPINION on Genistein and Daidzein - SCCS/1641/22 Final versionU. Bernauer, L. Bodin, Q. Chaudhry, P.J. Coenraad, M. Dusinska, J. Ezendam, E. Gaffet, C. L. Galli, B. Granum, E. Panteri, V. Rogiers, Ch. Rousselle, M. Stepnik, T. Vanhaecke, S. Wijnhoven, N. Cabaton, A. Koutsodimou, W. Uter, N. von GoetzThe SCCS adopted this document by written procedure on 16 September 2022 (153 pages)Mise en ligne 23 Septembre 2022https://health.ec.europa.eu/publications/genistein-and-daidzein_enDetailsPublication date : 23 September 2022Author : Scientific Committee on Consumer Safety (SCCS)DescriptionSCCS members: U. Bernauer (Rapporteur Daidzein), L. Bodin, Q. Chaudhry (Rapporteur Genistein), P.J. Coenraads (Chairperson), M. Dusinska, J. Ezendam, E. Gaffet, C.L. Galli (Rapporteur Genistein), B. Granum (former member), E. Panteri, V. Rogiers, Ch. Rousselle (Rapporteur Daidzein), M. Stepnik, T. Vanhaecke, S. WijnhovenSCCS external experts: N. Cabaton, A. Koutsodimou, W. Uter, N. von GoetzContact:SANTE-SCCS@ec.europa.euOn request from: European CommissionSCCS Number: SCCS/1641/22Adopted on: 16 September 2022Conclusion of the opinion: (1) In light of the data provided and taking under consideration the concerns related to potential endocrine disrupting properties of phytoestrogens,(a) does the SCCS consider genistein safe when used in cosmetic products up to a maximum concentration of 0.007%?(b) does the SCCS consider daidzein safe when used in cosmetic products up to a maximum concentration of 0.02%?From the safety assessment based on the available relevant data on the aglycone form of genistein and daidzein, and in consideration of the potential endocrine disrupting properties of phytoestrogens, the SCCS considers that:a) the use of genistein (CAS No 446-72-0, EC No 207-174-9) in cosmetic products up to a maximum concentration of 0.007% is safe.b) the use of daidzein (CAS No 486-66-8, EC No 207-635-4) in cosmetic products up to a maximum concentration of 0.02% is safe. (2) Alternatively, according to the SCCS what is the maximum concentration of genistein and daidzein that is considered safe for individual and combined use in cosmetic products?/(3) Does the SCCS have any further scientific concerns with regard to the use of genistein and daidzein or other related phytoestrogens in cosmetic products?/Keywords:SCCS, scientific opinion, genistein (CAS No 446-72-0, EC No 207-174-9), daidzein (CAS No 486-66-8, EC No 207-635-4), Regulation 1223/2009Opinion to be cited as:SCCS (Scientific Committee on Consumer Safety), Scientific opinion on genistein and daidzein, preliminary version of 12 January 2022, final version of 16 September 2022, SCCS/1641/22.
- Published
- 2022